phenotype and functional changes of vγ9vδ2 t lymphocytes in beh？ets disease and the effect of infliximab on vγ9vδ2 t cell expansion, activation and cytotoxicityvγ9vδ2 t淋巴细胞表型和功能变化在本·等病和英夫利昔单抗vγ9vδ2 t细胞扩张的影响,活化和细胞毒性.pdfVIP

Accardo-Palumbo et al. Arthritis Research Therapy 2010, 12:R109 /content/12/3/R109 R E S E A R C H A R T I C L E Open Access Research article Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçets disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity Antonina Accardo-Palumbo, Anna Rita Giardina, Francesco Ciccia, Angelo Ferrante, Alfonso Principato, Rosalia Impastato, Ennio Giardina and Giovanni Triolo* Abstract Introduction: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that has been introduced recently for Behçets disease (BD) patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vγ9/Vδ2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. Methods: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vγ9/Vδ2 T lymphocytes by means of fluorescence-activated cell sorter analysis of lymphocyte cultures from patients with active and inactive BD and healthy subjects. Results: Cell expansion, expression of TNFRII, perforin and gamma IFN content and release of granzyme A were significantly higher in active patients. In vitro and ex vivo treatment with infliximab resulted in a significant reduction of all parameters together with changes in the phenotype of Vγ9/Vδ2 T cells. Conclusions: All together these data indicate that infliximab is capable of interfering with Vγ9/Vδ2 T cell function in BD and although cell culture models cannot reliably predict all potential effects of the drug in vivo, our results present the possibility that this drug m